ABSTRACT

Asparaginase is an enzyme used in the treatment of leukemia. Its antileucemic effect is believed to result from the depletion of circulating asparagine. Major side effects are anaphylaxis, pancreatitis, diabetes, coagulation abnormalities, and thrombosis. Hyperglycemia is a well known but a rare side effect of L-asparaginase (L-ASP). The reported incidences vary widely from 1% to 14% in recipients of L-ASP alone, 2 to 11% in recipients of both L-ASP and prednisone, and only about 0.2% in those receiving prednisone alone. Age, obesity and Down syndrome were contributing factors to the increased risk of hyperglycemia.

We evaluate hyperglycemia risk factors in leukemia by presenting a case who develops hyperglycemia during the treatment.